

## WHO/IVR State of the Art of New Vaccines: Research and Development

### References Respiratory Syncytial Virus (RSV)

- Bitko, V, Musiyenko, A, Shulyayeva, O & Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. *Nat Med* 2005, **11**(1), 50-55.
- Counihan, ME, Shay, DK, Holman, RC, Lowther, SA & Anderson, LJ. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. *Pediatr Infect Dis J* 2001, **20**(7), 646-653.
- Durbin, AP & Karron, RA. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. *Clin Infect Dis* 2003, **37**(12), 1668-1677.
- Falsey, AR & Walsh, EE. Respiratory syncytial virus infection in adults. *Clin Microbiol Rev* 2000, **13**(3), 371-384.
- Glezen, WP, Taber, LH, Frank, AL & Kasel, JA. Risk of primary infection and reinfection with respiratory syncytial virus. *Am J Dis Child* 1986, **140**(6), 543-546.
- Karron, RA. Respiratory syncytial Virus Vaccine. In *Vaccines fourth edition* (Eds. Plotkin, S.A. & Orenstein, W.A.) Elsevier, USA, 2004. 1317-1326.
- Muller-Pebody, B, Edmunds, WJ, Zambon, MC, Gay, NJ & Crowcroft, NS. Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995-March 1998. *Epidemiol Infect* 2002, **129**(1), 99-106.
- Piedra, PA, Grace, S, Jewell, A *et al.* Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. *Pediatr Infect Dis J* 1998, **17**(3), 217-224.
- Polack, FP, Teng, MN, Collins, PL *et al.* A role for immune complexes in enhanced respiratory syncytial virus disease. *J Exp Med* 2002, **196**(6), 859-865.
- Robertson, SE, Roca, A, Alonso, P *et al.* Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. *Bull World Health Organ* 2004, **82**(12), 914-922.
- Russell, CJ, Jardetzky, TS & Lamb, RA. Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. *Embo J* 2001, **20**(15), 4024-4034.
- Schmidt, AC, McAuliffe, JM, Murphy, BR & Collins, PL. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. *J Virol* 2001, **75**(10), 4594-4603.
- Simoes, EA. Immunoprophylaxis of respiratory syncytial virus: global experience. *Respir Res* 2002, **3 Suppl 1**, S26-33.
- Skiadopoulos, MH, Surman, SR, Riggs, JM *et al.* Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. *Virology* 2002, **297**(1), 153-160.
- Tang, RS, MacPhail, M, Schickli, JH *et al.* Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys. *J Virol* 2004, **78**(20), 11198-11207.
- Tao, T, Skiadopoulos, MH, Durbin, AP, Davoodi, F, Collins, PL & Murphy, BR. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete

resistance to PIV1 challenge and partial resistance to PIV3 challenge. *Vaccine* 1999, **17**(9-10), 1100-1108.

Weber, MW, Mulholland, EK & Greenwood, BM. Respiratory syncytial virus infection in tropical and developing countries. *Trop Med Int Health* 1998, **3**(4), 268-280.

WHO, Changing History. in *The World Health Report* World Health Organ, 2004.

Wright, PF, Karron, RA, Belshe, RB *et al.* Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. *J Infect Dis* 2000, **182**(5), 1331-1342.